Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021
September 09 2021 - 7:00AM
Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers, today announced that six abstracts have been
accepted for poster presentation at the upcoming European Society
for Medical Oncology (ESMO) Congress, being held virtually
September 16-21, 2021.
Poster Presentation Details:
Title: Pharmacodynamic evidence for WEE1 target
engagement in surrogate and tumor tissues from a Phase 1 study of
the WEE1 inhibitor ZN-c3Abstract ID: 3874
Title: A Phase 1b dose-escalation study of
ZN-c3, a WEE1 inhibitor, in combination with chemotherapy in
patients with platinum-resistant or -refractory ovarian,
peritoneal, or fallopian tube cancerAbstract ID:
3912
Title: A Phase 1/2 dose-escalation and
expansion study of ZN-c5, an oral selective estrogen receptor
degrader (SERD), as monotherapy and in combination with palbociclib
in patients with advanced estrogen receptor (ER)+/HER2- breast
cancerAbstract ID: 3825
Title: A Phase 1b dose-escalation study of
ZN-c5, an oral selective estrogen receptor degrader (SERD), in
combination with abemaciclib in patients with advanced estrogen
receptor (ER)+/HER2- breast cancerAbstract ID:
3711
Title: A Phase 1 dose-escalation study of
ZN-d5, an BCL-2 inhibitor with improved selectivity, in subjects
with advanced non-Hodgkin lymphoma (NHL) or acute myeloid leukemia
(AML)Abstract ID: 4102
Title: Discovery of ZN-d5, a potent BCL-2
inhibitor with improved selectivity for BCL-2Abstract
ID: 3916
All posters will be available on the Congress platform beginning
September 16, 2021 at 8:30 a.m. CEST. The presentation materials
will also be available in the “Supporting Publications” section of
Zentalis Pharmaceutical’s website at www.zentalis.com.
About Zentalis Pharmaceuticals
Zentalis Pharmaceuticals, Inc. is a clinical-stage
biopharmaceutical company focused on discovering and developing
small molecule therapeutics targeting fundamental biological
pathways of cancers. The Company is developing a broad pipeline of
potentially best-in-class oncology candidates, all internally
discovered, which include ZN-c3, a WEE1 inhibitor for advanced
solid tumors, ZN-c5, an oral selective estrogen receptor degrader
(SERD) for ER+/HER2- breast cancer, ZN-d5, a BCL-2 inhibitor for
hematologic malignancies, and ZN-e4, an EGFR inhibitor for
non-small cell lung carcinoma (NSCLC). Zentalis has licensed ZN-c3,
ZN-c5 and ZN-d5 to its majority-owned joint venture, Zentera
Therapeutics, to develop and commercialize these candidates in
China. Zentalis has operations in both New York and San Diego.
For more information, please visit www.zentalis.com. Follow
Zentalis on Twitter at @ZentalisP and on LinkedIn
at www.linkedin.com/company/zentalis-pharmaceuticals.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including without limitation statements
regarding our expectations surrounding the development, potential,
safety, efficacy, and regulatory and clinical progress of our
product candidates in the Unites States and globally, and upcoming
events and presentations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause our actual results,
performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by
the forward-looking statements, including, but not limited to the
important factors discussed under the caption “Risk Factors” in our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2021
filed with the U.S. Securities and Exchange Commission (SEC) and
our other filings with the SEC. Any such forward-looking statements
represent management’s estimates as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to
change.Investor Contact:Gitanjali Jain
OgawaSolebury Troutgogawa@soleburytrout.com
Media Contact:Julia DeutschSolebury
Troutjdeutsch@soleburytrout.com
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zentalis Pharmaceuticals (NASDAQ:ZNTL)
Historical Stock Chart
From Sep 2023 to Sep 2024